In this article
Milestone Pharmaceuticals shares are trading lower after receiving a complete response letter from the FDA, delaying the launch of its etripamil nasal spray until the first half of 2026.
Milestone Pharmaceuticals shares are trading lower after receiving a complete response letter from the FDA, delaying the launch of its etripamil nasal spray until the first half of 2026.
